BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Koivisto VA, Pelkonen R, Cantell K. Effect of interferon on glucose tolerance and insulin sensitivity. Diabetes. 1989;38:641-647. [PMID: 2653935 DOI: 10.2337/diab.38.5.641] [Cited by in Crossref: 65] [Cited by in F6Publishing: 67] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Surendran A, Bhalla A, Whyte MB. Improved diabetes control, allowing insulin cessation, after direct acting antiviral treatment (DAAT) of hepatitis C. BMJ Case Rep 2022;15:e243491. [PMID: 35450872 DOI: 10.1136/bcr-2021-243491] [Reference Citation Analysis]
2 Wang L, Chen K, Wang M, Lv Z, Gu W, Wang X, Ni Q, Mu Y. Characteristics of Interferon-Associated Diabetes Mellitus in Past 30 Years: A Review. Horm Metab Res 2022;54:145-52. [PMID: 35276739 DOI: 10.1055/a-1749-5716] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Casey KA, Smith MA, Sinibaldi D, Seto NL, Playford MP, Wang X, Carlucci PM, Wang L, Illei G, Yu B, Wang S, Remaley AT, Mehta NN, Kaplan MJ, White WI. Modulation of Cardiometabolic Disease Markers by Type I Interferon Inhibition in Systemic Lupus Erythematosus. Arthritis Rheumatol 2021;73:459-71. [DOI: 10.1002/art.41518] [Cited by in Crossref: 8] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
4 Shafiei-Jahani P, Hurrell BP, Galle-Treger L, Helou DG, Howard E, Painter J, Lo R, Lewis G, Soroosh P, Akbari O. DR3 stimulation of adipose resident ILC2s ameliorates type 2 diabetes mellitus. Nat Commun 2020;11:4718. [PMID: 32948777 DOI: 10.1038/s41467-020-18601-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
5 Chan CC, Damen MSMA, Moreno-Fernandez ME, Stankiewicz TE, Cappelletti M, Alarcon PC, Oates JR, Doll JR, Mukherjee R, Chen X, Karns R, Weirauch MT, Helmrath MA, Inge TH, Divanovic S. Type I interferon sensing unlocks dormant adipocyte inflammatory potential. Nat Commun 2020;11:2745. [PMID: 32488081 DOI: 10.1038/s41467-020-16571-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
6 Jiang N, Li Y, Shu T, Wang J. Cytokines and inflammation in adipogenesis: an updated review. Front Med. 2019;13:314-329. [PMID: 30066061 DOI: 10.1007/s11684-018-0625-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 37] [Article Influence: 6.7] [Reference Citation Analysis]
7 Mráz M, Cinkajzlová A, Kloučková J, Lacinová Z, Kratochvílová H, Lipš M, Pořízka M, Kopecký P, Lindner J, Kotulák T, Netuka I, Haluzík M. Dendritic Cells in Subcutaneous and Epicardial Adipose Tissue of Subjects with Type 2 Diabetes, Obesity, and Coronary Artery Disease. Mediators Inflamm 2019;2019:5481725. [PMID: 31210749 DOI: 10.1155/2019/5481725] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
8 Chan CC, Damen MSMA, Alarcon PC, Sanchez-Gurmaches J, Divanovic S. Inflammation and Immunity: From an Adipocyte's Perspective. J Interferon Cytokine Res 2019;39:459-71. [PMID: 30920343 DOI: 10.1089/jir.2019.0014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
9 Lombardi A, Tsomos E, Hammerstad SS, Tomer Y. Interferon alpha: The key trigger of type 1 diabetes. J Autoimmun. 2018;94:7-15. [PMID: 30115527 DOI: 10.1016/j.jaut.2018.08.003] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 8.8] [Reference Citation Analysis]
10 Šestan M, Marinović S, Kavazović I, Cekinović Đ, Wueest S, Turk Wensveen T, Brizić I, Jonjić S, Konrad D, Wensveen FM, Polić B. Virus-Induced Interferon-γ Causes Insulin Resistance in Skeletal Muscle and Derails Glycemic Control in Obesity. Immunity 2018;49:164-177.e6. [PMID: 29958802 DOI: 10.1016/j.immuni.2018.05.005] [Cited by in Crossref: 46] [Cited by in F6Publishing: 75] [Article Influence: 11.5] [Reference Citation Analysis]
11 Ganguly D. Do Type I Interferons Link Systemic Autoimmunities and Metabolic Syndrome in a Pathogenetic Continuum? Trends Immunol. 2018;39:28-43. [PMID: 28826817 DOI: 10.1016/j.it.2017.07.001] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 6.4] [Reference Citation Analysis]
12 Khan WA. Recombinant Interferon Alpha-2b is a High-Affinity Antigen for Type 1 Diabetes Autoantibodies. Can J Diabetes 2017;41:217-23. [PMID: 28024793 DOI: 10.1016/j.jcjd.2016.10.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
13 Mullen M, Gonzalez-Perez RR. Leptin-Induced JAK/STAT Signaling and Cancer Growth. Vaccines (Basel). 2016;4:pii: E26. [PMID: 27472371 DOI: 10.3390/vaccines4030026] [Cited by in Crossref: 52] [Cited by in F6Publishing: 67] [Article Influence: 8.7] [Reference Citation Analysis]
14 Lee K, Um SH, Rhee DK, Pyo S. Interferon-alpha inhibits adipogenesis via regulation of JAK/STAT1 signaling. Biochim Biophys Acta 2016;1860:2416-27. [PMID: 27424923 DOI: 10.1016/j.bbagen.2016.07.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
15 Sotoodeh Jahromi A, Sanie MS, Yusefi A, Zabetian H, Zareian P, Hakimelahi H, Madani A, Hojjat-Farsangi M. Association of Tumor Growth Factor-β and Interferon-γ Serum Levels With Insulin Resistance in Normal Pregnancy. Glob J Health Sci 2015;8:25-32. [PMID: 26755467 DOI: 10.5539/gjhs.v8n6p25] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
16 Hammerstad SS, Grock SF, Lee HJ, Hasham A, Sundaram N, Tomer Y. Diabetes and Hepatitis C: A Two-Way Association. Front Endocrinol (Lausanne). 2015;6:134. [PMID: 26441826 DOI: 10.3389/fendo.2015.00134] [Cited by in Crossref: 47] [Cited by in F6Publishing: 50] [Article Influence: 6.7] [Reference Citation Analysis]
17 Takci Z, Karadag AS, Ertugrul DT, Bilgili SG. Elevated insulin resistance in patients with recurrent aphthous stomatitis. Clin Oral Invest 2015;19:1193-7. [DOI: 10.1007/s00784-014-1339-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
18 Antonelli A, Ferrari SM, Giuggioli D, Di Domenicantonio A, Ruffilli I, Corrado A, Fabiani S, Marchi S, Ferri C, Ferrannini E, Fallahi P. Hepatitis C virus infection and type 1 and type 2 diabetes mellitus. World J Diabetes 2014; 5(5): 586-600 [PMID: 25317237 DOI: 10.4239/wjd.v5.i5.586] [Cited by in CrossRef: 62] [Cited by in F6Publishing: 56] [Article Influence: 7.8] [Reference Citation Analysis]
19 Zhao P, Stephens JM. Identification of STAT target genes in adipocytes. JAKSTAT 2013;2:e23092. [PMID: 24058802 DOI: 10.4161/jkst.23092] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
20 Murdolo G, Francisci D, Forini F, Baldelli F, Angeletti G, Stagni G, Santeusanio F, Calcinaro F, Falorni A. Expression of endocrine autoantibodies in chronic hepatitis C, before and after interferon-α therapy. J Endocrinol Invest 2002;25:938-46. [DOI: 10.1007/bf03344065] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
21 Richard AJ, Stephens JM. The role of JAK-STAT signaling in adipose tissue function. Biochim Biophys Acta 2014;1842:431-9. [PMID: 23735217 DOI: 10.1016/j.bbadis.2013.05.030] [Cited by in Crossref: 86] [Cited by in F6Publishing: 99] [Article Influence: 9.6] [Reference Citation Analysis]
22 Eslam M, Aparcero R, Mousa YI, Grande L, Shaker Y, Ali A, Del Campo JA, Khattab MA, Romero-Gomez M. Insulin resistance impairs viral dynamics independently of ethnicity or genotypes. J Clin Gastroenterol. 2012;46:228-234. [PMID: 22298085 DOI: 10.1097/mcg.0b013e31822a2dc6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
23 Brandman D, Bacchetti P, Ayala CE, Maher JJ, Khalili M. Impact of insulin resistance on HCV treatment response and impact of HCV treatment on insulin sensitivity using direct measurements of insulin action. Diabetes Care. 2012;35:1090-1094. [PMID: 22399695 DOI: 10.2337/dc11-1837] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
24 Yagyu H, Okada K, Sato S, Yamashita Y, Okada N, Osuga J, Nagasaka S, Sugano K, Ishibashi S. Pegylated interferon-α2b and ribavirin combination therapy induces Hashitoxicosis followed by type 1 diabetes mellitus. Diabetes Res Clin Pract. 2012;95:e52-e54. [PMID: 22154462 DOI: 10.1016/j.diabres.2011.11.016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
25 Wada T, Hoshino M, Kimura Y, Ojima M, Nakano T, Koya D, Tsuneki H, Sasaoka T. Both type I and II IFN induce insulin resistance by inducing different isoforms of SOCS expression in 3T3-L1 adipocytes. American Journal of Physiology-Endocrinology and Metabolism 2011;300:E1112-23. [DOI: 10.1152/ajpendo.00370.2010] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 3.0] [Reference Citation Analysis]
26 Richard AJ, Stephens JM. Emerging roles of JAK-STAT signaling pathways in adipocytes. Trends Endocrinol Metab 2011;22:325-32. [PMID: 21561789 DOI: 10.1016/j.tem.2011.03.007] [Cited by in Crossref: 58] [Cited by in F6Publishing: 65] [Article Influence: 5.3] [Reference Citation Analysis]
27 Nakanishi K, Saitoh S. Clinical and genetic characteristics of patients with type 1 diabetes associated with interferon therapy. Diabetes Care 2011;34:471-3. [PMID: 21270202 DOI: 10.2337/dc10-1237] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
28 Khattab M, Eslam M, Sharwae MA, Shatat M, Ali A, Hamdy L. Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients. Am J Gastroenterol 2010;105:1970-7. [PMID: 20234345 DOI: 10.1038/ajg.2010.110] [Cited by in Crossref: 58] [Cited by in F6Publishing: 61] [Article Influence: 4.8] [Reference Citation Analysis]
29 Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI. Clearance of HCV by Combination Therapy of Pegylated Interferon alpha-2a and Ribavirin Improves Insulin Resistance. Gut Liver. 2009;3:108-115. [PMID: 20431732 DOI: 10.5009/gnl.2009.3.2.108] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
30 Lo Y, Chang S, Sheng W, Hung C, Chang S. Association of pancreatic autoantibodies and human leukocyte antigen haplotypes with resolution of diabetes mellitus after therapy for hepatitis C virus infection in patients with HIV infection: case report and review of literature: . European Journal of Gastroenterology & Hepatology 2009;21:478-81. [DOI: 10.1097/meg.0b013e328317f4c8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
31 Soetekouw PM, Koopman M, Burger D, Tjan-Heijnen VC, De Mulder PH. Severe hyponatremia caused by hyperglycaemia due to interferon alpha therapy in advanced renal cell carcinoma. Acta Oncol 2009;48:154-6. [PMID: 19101828 DOI: 10.1080/02841860802047403] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
32 Negro F. Peroxisome proliferator-activated receptors and hepatitis C virus-induced insulin resistance. PPAR Res. 2009;2009:483485. [PMID: 19132131 DOI: 10.1155/2009/483485] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 0.5] [Reference Citation Analysis]
33 Overbeck K, Genné D, Golay A, Negro F; Swiss Association for the Study of the Liver (SASL). Pioglitazone in chronic hepatitis C not responding to pegylated interferon-alpha and ribavirin. J Hepatol 2008;49:295-8. [PMID: 18555553 DOI: 10.1016/j.jhep.2008.03.033] [Cited by in Crossref: 58] [Cited by in F6Publishing: 57] [Article Influence: 4.1] [Reference Citation Analysis]
34 Nylen ES, Marathe IC, Khan IA, Azevedo R, Hirsch KR. Sudden onset of diabetic ketoacidosis during consensus interferon therapy for chronic viral hepatitis C. Am J Med Sci 2008;335:329-30. [PMID: 18414077 DOI: 10.1097/MAJ.0b013e318145a721] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
35 Stava CJ, Jimenez C, Vassilopoulou-Sellin R. Endocrine sequelae of cancer and cancer treatments. J Cancer Surviv 2007;1:261-74. [PMID: 18648961 DOI: 10.1007/s11764-007-0038-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
36 Dingli D, Wolf RC, Vella A. Imatinib and type 2 diabetes. Endocr Pract 2007;13:126-30. [PMID: 17490925 DOI: 10.4158/EP.13.2.126] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
37 Romero-Gómez M. Insulin resistance and hepatitis C. World J Gastroenterol. 2006;12:7075-7080. [PMID: 17131467 DOI: 10.1111/j.1478-3231.2010.02365.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
38 Soultati AS, Dourakis SP, Alexopoulou A, Deutsch M, Archimandritis AJ. Simultaneous development of diabetic ketoacidosis and Hashitoxicosis in a patient treated with pegylated interferon-alpha for chronic hepatitis C. World J Gastroenterol 2007; 13(8): 1292-1294 [PMID: 17451219 DOI: 10.3748/wjg.v13.i8.1292] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
39 Romero-Gómez M. Insulin resistance and hepatitis C. World J Gastroenterol 2006; 12(44): 7075-7080 [PMID: 17131467 DOI: 10.3748/wjg.v12.i44.7075] [Cited by in CrossRef: 112] [Cited by in F6Publishing: 103] [Article Influence: 7.0] [Reference Citation Analysis]
40 Delano MJ, Moldawer LL. The origins of cachexia in acute and chronic inflammatory diseases. Nutr Clin Pract 2006;21:68-81. [PMID: 16439772 DOI: 10.1177/011542650602100168] [Cited by in Crossref: 130] [Cited by in F6Publishing: 113] [Article Influence: 8.1] [Reference Citation Analysis]
41 Sleijfer S, Bannink M, Van Gool AR, Kruit WH, Stoter G. Side effects of interferon-alpha therapy. Pharm World Sci. 2005;27:423-431. [PMID: 16341948 DOI: 10.1007/s11096-005-1319-7] [Cited by in Crossref: 129] [Cited by in F6Publishing: 134] [Article Influence: 8.1] [Reference Citation Analysis]
42 Erdem H, Dinc A, Pay S, Simsek I, Turan M. Peripheral insulin resistance in patients with Behcet's disease. J Eur Acad Dermatol Venerol 2006;20:391-5. [DOI: 10.1111/j.1468-3083.2006.01457.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
43 Bahtiyar G, Shin JJ, Aytaman A, Sowers JR, McFarlane SI. Association of diabetes and hepatitis C infection: epidemiologic evidence and pathophysiologic insights. Curr Diab Rep. 2004;4:194-198. [PMID: 15132884 DOI: 10.1007/s11892-004-0023-7] [Cited by in Crossref: 53] [Cited by in F6Publishing: 42] [Article Influence: 2.9] [Reference Citation Analysis]
44 Devendra D, Eisenbarth GS. Interferon alpha--a potential link in the pathogenesis of viral-induced type 1 diabetes and autoimmunity. Clin Immunol. 2004;111:225-233. [PMID: 15183143 DOI: 10.1016/j.clim.2004.01.008] [Cited by in Crossref: 71] [Cited by in F6Publishing: 70] [Article Influence: 3.9] [Reference Citation Analysis]
45 Fabris P, Floreani A, Tositti G, Vergani D, De Lalla F, Betterle C. Type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy. Aliment Pharmacol Ther 2003;18:549-58. [PMID: 12969081 DOI: 10.1046/j.1365-2036.2003.01681.x] [Cited by in Crossref: 92] [Cited by in F6Publishing: 63] [Article Influence: 4.8] [Reference Citation Analysis]
46 Jabr FI, Ordinario MMD. Sudden onset of diabetic ketoacidosis during pegylated interferon alfa therapy. The American Journal of Medicine 2003;115:158-9. [DOI: 10.1016/s0002-9343(03)00301-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
47 Chen LK, Hwang SJ, Tsai ST, Luo JC, Lee SD, Chang FY. Glucose intolerance in Chinese patients with chronic hepatitis C. World J Gastroenterol 2003; 9(3): 505-508 [PMID: 12632506 DOI: 10.3748/wjg.v9.i3.505] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 15] [Article Influence: 0.7] [Reference Citation Analysis]
48 Mofredj A, Howaizi M, Grasset D, Licht H, Loison S, Devergie B, Demontis R, Cadranel JF. Diabetes mellitus during interferon therapy for chronic viral hepatitis. Dig Dis Sci. 2002;47:1649-1654. [PMID: 12141831 DOI: 10.1023/A:1015852110353] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
49 Recasens M, Aguilera E, Ampurdanés S, Sánchez Tapias JM, Simó O, Casamitjana R, Conget I. Abrupt onset of diabetes during interferon-alpha therapy in patients with chronic hepatitis C. Diabet Med. 2001;18:764-767. [PMID: 11606177 DOI: 10.1046/j.1464-5491.2001.00562.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
50 Mizock BA. Alterations in fuel metabolism in critical illness: hyperglycaemia. Best Practice & Research Clinical Endocrinology & Metabolism 2001;15:533-51. [DOI: 10.1053/beem.2001.0168] [Cited by in Crossref: 233] [Cited by in F6Publishing: 216] [Article Influence: 11.1] [Reference Citation Analysis]
51 Floyd ZE, Stephens JM. Interferon-gamma-mediated activation and ubiquitin-proteasome-dependent degradation of PPARgamma in adipocytes. J Biol Chem 2002;277:4062-8. [PMID: 11733495 DOI: 10.1074/jbc.M108473200] [Cited by in Crossref: 140] [Cited by in F6Publishing: 140] [Article Influence: 6.7] [Reference Citation Analysis]
52 Hogan JC, Stephens JM. The identification and characterization of a STAT 1 binding site in the PPARgamma2 promoter. Biochem Biophys Res Commun 2001;287:484-92. [PMID: 11554754 DOI: 10.1006/bbrc.2001.5606] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 1.2] [Reference Citation Analysis]
53 Hardy H, Esch LD, Morse GD. Glucose disorders associated with HIV and its drug therapy. Ann Pharmacother 2001;35:343-51. [PMID: 11261533 DOI: 10.1345/aph.10044] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.2] [Reference Citation Analysis]
54 Bhatti A, McGarrity TJ, Gabbay R. Diabetic ketoacidosis induced by alpha interferon and ribavirin treatment in a patient with hepatitis C. Am J Gastroenterol. 2001;96:604-605. [PMID: 11232722 DOI: 10.1111/j.1572-0241.2001.03571.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
55 Wesche B, Jaeckel E, Trautwein C, Wedemeyer H, Falorni A, Frank H, von zur Mühlen A, Manns MP, Brabant G. Induction of autoantibodies to the adrenal cortex and pancreatic islet cells by interferon alpha therapy for chronic hepatitis C. Gut 2001;48:378-83. [PMID: 11171829 DOI: 10.1136/gut.48.3.378] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 2.2] [Reference Citation Analysis]
56 Konrad T, Zeuzem S, Vicini P, Toffolo G, Briem D, Lormann J, Herrmann G, Berger A, Kusterer K, Teuber G. Evaluation of factors controlling glucose tolerance in patients with HCV infection before and after 4 months therapy with interferon-alpha. Eur J Clin Invest. 2000;30:111-121. [PMID: 10651835 DOI: 10.1046/j.1365-2362.2000.00608.x] [Cited by in Crossref: 67] [Cited by in F6Publishing: 60] [Article Influence: 3.0] [Reference Citation Analysis]
57 Khanna S, Roy S, Packer L, Sen CK. Cytokine-induced glucose uptake in skeletal muscle: redox regulation and the role of alpha-lipoic acid. Am J Physiol 1999;276:R1327-33. [PMID: 10233023 DOI: 10.1152/ajpregu.1999.276.5.R1327] [Cited by in Crossref: 4] [Cited by in F6Publishing: 15] [Article Influence: 0.2] [Reference Citation Analysis]
58 Yawata N, Nakamura S, Kijima M, Ikai N, Kanai M, Sugita M, Ohno S. High incidence of glucose intolerance in Vogt-Koyanagi-Harada disease. Br J Ophthalmol 1999;83:39-42. [PMID: 10209432 DOI: 10.1136/bjo.83.1.39] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.3] [Reference Citation Analysis]
59 Ebeling P, Koistinen HA, Koivisto VA. Insulin-independent glucose transport regulates insulin sensitivity. FEBS Letters 1998;436:301-3. [DOI: 10.1016/s0014-5793(98)01149-1] [Cited by in Crossref: 68] [Cited by in F6Publishing: 79] [Article Influence: 2.8] [Reference Citation Analysis]
60 Yeung SC, Chiu AC, Vassilopoulou-Sellin R, Gagel RF. The endocrine effects of nonhormonal antineoplastic therapy. Endocr Rev 1998;19:144-72. [PMID: 9570035 DOI: 10.1210/edrv.19.2.0328] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 1.5] [Reference Citation Analysis]
61 Pelegrin M, Devedjian JC, Costa C, Visa J, Solanes G, Pujol A, Asins G, Valera A, Bosch F. Evidence from transgenic mice that interferon-beta may be involved in the onset of diabetes mellitus. J Biol Chem 1998;273:12332-40. [PMID: 9575186 DOI: 10.1074/jbc.273.20.12332] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 1.4] [Reference Citation Analysis]
62 Lopes EP, Silva AE, Sette Junior H, Guimarães RX, Ferraz ML. Autoantibodies before, during and after administration of recombinant interferon-alpha for chronic viral hepatitis. Rev Inst Med Trop Sao Paulo 1995;37:455-60. [PMID: 8729757 DOI: 10.1590/s0036-46651995000500012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
63 Campbell S, Mclaren EH, Danesh BJ. Rapidly reversible increase in insulin requirement with interferon. BMJ. 1996;313:92. [PMID: 8688762 DOI: 10.1136/bmj.313.7049.92a] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
64 Pardo M, Marriott E, Moliner MC, Quiroga JA, Carreño V. Risks and benefits of interferon-alpha in the treatment of hepatitis. Drug Saf 1995;13:304-16. [PMID: 8785018 DOI: 10.2165/00002018-199513050-00004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
65 Gori A, Caredda F, Franzetti F, Ridolfo A, Rusconi S, Moroni M. Reversible diabetes in patient with AIDS-related Kaposi's sarcoma treated with interferon α-2a. The Lancet 1995;345:1438-9. [DOI: 10.1016/s0140-6736(95)92628-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 0.7] [Reference Citation Analysis]
66 Raheja BS, Sadikot SM, Phatak RB, Rao MB. Significance of the N-6/N-3 Ratio for Insulin Action in Diabetes. Ann NY Acad Sci 1993;683:258-71. [DOI: 10.1111/j.1749-6632.1993.tb35715.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 1.8] [Reference Citation Analysis]
67 Grunfeld C, Feingold KR. The metabolic effects of tumor necrosis factor and other cytokines. Biotherapy 1991;3:143-58. [PMID: 2054255 DOI: 10.1007/BF02172087] [Cited by in Crossref: 122] [Cited by in F6Publishing: 116] [Article Influence: 3.9] [Reference Citation Analysis]